Beijing Balance Medical Technology Co.,Ltd. (688198.SH) announced that its subsidiary Beijing Aibrun Biotechnology has received regulatory approval for its collagen implant product (Collagen Fiber Filler-I) from China's National Medical Products Administration. This marks China's first dermal collagen injection specifically designed to enhance facial smoothness in the cheek area.
The product features naturally cross-linked intact Type I collagen fibers (Collagen Fibrils&Fibers) with stable triple-helix structures that self-assemble into ordered fibrous supramolecular structures. By replenishing the dermal collagen framework, it improves extracellular matrix metabolism, restoring skin elasticity and luminosity while maintaining optimal tissue texture and viscoelasticity.
Key innovations include proprietary ultra-pure extraction technology and precise telopeptide removal, ensuring amino acid sequence alignment with human Type I collagen at the molecular level. Clinical trials confirmed immunogenicity matching natural human collagen. As a full-length collagen molecule, it maintains complete triple-helix integrity, while its high purity enables spontaneous fiber assembly - distinguishing it structurally and qualitatively from existing collagen injections.
This breakthrough builds upon the company's longstanding collagen research, developed by its molecular biology and biochemistry R&D center. The product's launch establishes a foundation for future development of quantitatively cross-linked Type II collagen and ribose-cross-linked Type III collagen. It also provides ultra-pure full-length collagen for functional applications including valve anchoring stents, aortic root patches, and tissue therapy products as coating/drug-carrying matrices.
This approval represents another milestone for the company's proprietary animal-derived implant materials platform, demonstrating its integrated R&D capabilities.
Comments